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REPORT
Biallelic Mutations in ATP5F1D, which Encodes
a Subunit of ATP Synthase, Cause a Metabolic Disorder
Monika Ola´hova´,1,24 Wan Hee Yoon,2,3,23,24 Kyle Thompson,1,24 Sharayu Jangam,3 Liliana Fernandez,4
Jean M. Davidson,4 Jennifer E. Kyle,5 Megan E. Grove,6 Dianna G. Fisk,6 Jennefer N. Kohler,4
Matthew Holmes,1 Annika M. Dries,4 Yong Huang,4 Chunli Zhao,4 Ke´vin Contrepois,7
Zachary Zappala,7 Laure Fre´sard,8 Daryl Waggott,4 Erika M. Zink,5 Young-Mo Kim,5 Heino M. Heyman,5
Kelly G. Stratton,9 Bobbie-Jo M. Webb-Robertson,9 Undiagnosed Diseases Network, Michael Snyder,7
Jason D. Merker,6,8 Stephen B. Montgomery,7,8 Paul G. Fisher,4 Rene´ G. Feichtinger,10
Johannes A. Mayr,10 Julie Hall,11 Ines A. Barbosa,12 Michael A. Simpson,12 Charu Deshpande,13
Katrina M. Waters,5 David M. Koeller,14 Thomas O. Metz,5 Andrew A. Morris,15,16 Susan Schelley,17
Tina Cowan,8 Marisa W. Friederich,18 Robert McFarland,1 Johan L.K. Van Hove,18 Gregory M. Enns,17
Shinya Yamamoto,3,19,20,21 Euan A. Ashley,4,6,7,22 Michael F. Wangler,3,20 Robert W. Taylor,1
Hugo J. Bellen,2,3,19,20,21 Jonathan A. Bernstein,4,17 and Matthew T. Wheeler4,22,25,*
ATP synthase, Hþ transporting, mitochondrial F1 complex, d subunit (ATP5F1D; formerly ATP5D) is a subunit of mitochondrial ATP
synthase and plays an important role in coupling proton translocation and ATP production. Here, we describe two individuals, each
with homozygous missense variants in ATP5F1D, who presented with episodic lethargy, metabolic acidosis, 3-methylglutaconic acidu-
ria, and hyperammonemia. Subject 1, homozygous for c.245C>T (p.Pro82Leu), presented with recurrent metabolic decompensation
starting in the neonatal period, and subject 2, homozygous for c.317T>G (p.Val106Gly), presented with acute encephalopathy in
childhood. Cultured skin fibroblasts from these individuals exhibited impaired assembly of F1FO ATP synthase and subsequent reduced
complex Vactivity. Cells from subject 1 also exhibited a significant decrease inmitochondrial cristae. Knockdown ofDrosophila ATPsynd,
the ATP5F1D homolog, in developing eyes and brains caused a near complete loss of the fly head, a phenotype that was fully rescued by
wild-type human ATP5F1D. In contrast, expression of the ATP5F1D c.245C>T and c.317T>G variants rescued the head-size phenotype
but recapitulated the eye and antennae defects seen in other genetic models of mitochondrial oxidative phosphorylation deficiency.
Our data establish c.245C>T (p.Pro82Leu) and c.317T>G (p.Val106Gly) in ATP5F1D as pathogenic variants leading to a Mendelian
mitochondrial disease featuring episodic metabolic decompensation.Mitochondrial diseases are clinically and genetically
heterogeneous. Findings such as hyperammonemia, lactic
acidosis, and rhabdomyolysis suggest mitochondrial
dysfunction and can occur as a result of defects in fatty
acid oxidation as well as disorders of the respiratory chain.
Defects in the electron transport chain (ETC), which
underlies oxidative phosphorylation (OXPHOS), can be
caused by mutations in the nuclear or mitochondrial
genome.1,2 Accordingly, inheritance can be autosomal,
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chronic progressive disorders of adulthood.
Complex V is the final multi-subunit complex of the
OXPHOS system. It harnesses energy from the proton elec-
trochemical gradient to synthesize ATP from ADP3 and
inorganic phosphate, which is the main source of energy
for intracellular metabolic pathways.4 Mitochondrial ATP
synthase consists of twomain functional domains, the sol-
uble F1 catalytic portion in the mitochondrial matrix and
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to pass from the intermembrane space to the matrix
(reviewed by Jonckheere et al.5). Two subunits of the FO
(a and A6L) are encoded by mtDNA (MT-ATP6 and
MT-ATP8), whereas the other subunits and accessory fac-
tors are encoded by the nuclear genome. Although
mitochondrial disorders due to defects in mitochondrial
complex V have been reported, they are very rare in com-
parison with those due tomutations in the genes encoding
the proteins of the other complexes (I–IV).6,7
We report the clinical and genetic findings of two
children with suspected mitochondrial disease from unre-
lated families. Subject 1 is the only child of first-cousin
Mexican-American parents. On the second day of life,
she presented with lethargy and severe anion-gap acidosis.
Initial laboratory investigations showed hypoglycemia
(28 mg/dL [normal 45–100]), lactic acidosis (34 mmol/L
[normal < 2.1]), and hyperammonemia (359 mmol/L
[normal < 30]). Initial management included intravenous
fluids with dextrose and intravenous lipid administration.
Within 24 hr, lactic acid and ammonia had decreased to
4.8 mmol/L and 70 mmol/L, respectively. Ammonia-scav-
enging medications were not administered. Qualitative
organic acid studies showed moderate to marked elevation
of lactic, fumaric, malic, p-hydroxyphenyllactic, and
3-methylglutaconic acids. An acylcarnitine profile showed
nonspecific elevations of numerous short-, medium-, and
long-chain acylcarnitine species. Creatine kinase was not
assessed during her initial presentation. Brain MRI with
magnetic resonance spectroscopy was normal. Her most
recent evaluation was at 9 years of age. 3-methylglutaconic
aciduria has been a persistent finding in urine organic acid
analysis. She hasmild developmental delays and short stat-
ure. Between the ages of 1 and 4 years, she was noted
to have dilated cardiomyopathy and subsequent normali-
zation of resting systolic function. Ophthalmologic
examination at 8 years of age showed a prominentmacular
reflex. No other findings were noted. Neurologic examina-
tion at 9 years of age showedmild proximal weakness (4/5)
greater than distal weakness (5/5) in her extremities. She
additionally had gait imbalance and ankle contractures
with reduced reflexes (1þ). Cranial nerve examination
showed slightly decreased strength with eye closure. Cere-
bellar examination and sensation were normal. She has
had at least nine episodes of metabolic decompensation
manifesting with lactic acidosis and muscle breakdown,
which required hospital admission. During decompensa-
tion, serum creatine kinase has been repeatedly elevated
to greater than 500 U/L and as high as 1,109 U/L. These
episodes have been responsive to intravenous fluids with
dextrose. Severe hyperammonemia has not recurred since
the newborn period. She has been treated with oral supple-
ments including alpha-lipoic acid, ubiquinone, riboflavin,
thiamine, biotin, pantothenic acid, and ascorbic acid and
has experienced subjective improvement in her physical
stamina.
Subject 2 is the first child born to healthy first-cousin UK
Asianparents, andhehas a healthy younger brother. HewasThe Ameriborn at term by vacuum-assisted delivery after an unevent-
ful pregnancy. Therewerenoperinatal problems.His speech
was delayed, and he received speech therapy, but he other-
wise met typical developmental milestones. At age 4 years
and 10 months, he presented with an encephalopathic
illness after 24 hr of coryza and fever. He was witnessed to
have a progressive deterioration in the level of conscious-
ness over several hours and had a brief tonic-clonic seizure,
which was managed with phenobarbital. Ultimately, he
required intubation and mechanical ventilation, which
was maintained for 2 days. He had ketoacidosis and hyper-
ammonemia (maximum 262 mmol/L [normal < 30]).
Plasma lactate was 5.3 mmol/L (normal < 2.1) at presenta-
tion but decreased to 2.1 mmol/L within 5 hr and subse-
quently to 1.1 mmol/L, at which stage the cerebrospinal
fluid lactate was 1.8 mmol/L (normal < 2.5). Initial treat-
ment included intravenous fluids with dextrose, intrave-
nous carnitine (100 mg/kg/day), and sodium benzoate
(250 mg/kg/day). The ammonia level normalized within
24hr. Neuroimaging showed diffuse swelling of the cerebral
cortex bilaterally, especially in the temporal lobes, as well as
lesser changes in the cerebellar hemispheres (Figure S1).
There was swelling and signal change in the subcortical
and deep white matter, although the periventricular white
matter was spared. There were also signal changes in the
thalami, midbrain, pons, corpus callosum, and basal
ganglia. MRI 1 year later showed resolution of these
abnormal findings. The transient nature of theMRI findings
was interpreted as evidence that they might have reflected
the presence of edema that resolved over time. After this
episode, he made a full recovery to his prior baseline. He
attends a regular school, and at 6 years of age he had a
full-scale IQ of 81 (Wechsler Preschool and Primary Scale
of Intelligence8) and poor attention (as assessed by a score
of 51 [first percentile] on the Attention & Concentration
Index of the Children’s Memory Scale9). He now hasmildly
impaired exercise tolerance, tires easily, and uses a wheel-
chair for long distances. Neurologic examination after his
initial presentationnotedmildhypotonia, but thishas since
resolved. He has pes planus, pes adductus, and dyspraxia of
gait but no other abnormalities on detailed neurologic
examination. The cranial nerve, motor, sensory, and cere-
bellar examinations have otherwise been normal. On
recent routine evaluation, 12-lead electrocardiography and
echocardiography were normal. Organic acid analysis has
persistently shown a mild increase in 3-methylglutaconic
and 3-methylglutaric acid excretion. He has been a fussy
eater since infancy and receives much of his nutrition as
liquid formula.Heperiodicallydevelops lethargyandemesis
typically in association with febrile illness. Symptoms are
improvedbyoral dextrose containingfluids. He experiences
emesis approximately twice a week and has frequent stom-
ach aches. He has a history of intermittent squint and has
developed amblyopia of the left eye, despite patching of
the right eye. There are no other ophthalmological abnor-
malities. His linear growth has been typical for his age, and
physical examination shows no significant findings. Thecan Journal of Human Genetics 102, 494–504, March 1, 2018 495
parents and younger sibling (currently 4 years of age) are in
good health.
Informed consent for diagnostic and research studies
was obtained for both subjects in accordance with the
Declaration of Helsinki protocols and approved by the cen-
tral institutional review board (IRB) at the NIH National
Human Genome Research Institute for the Undiagnosed
Diseases Network (subject 1) and by the local IRB in
Newcastle upon Tyne, UK (subject 2).
Initial diagnostic analyses of cultured skin fibroblasts for
pyruvate carboxylase, pyruvate dehydrogenase, and
enzyme activities of respiratory chain complexes I–IV in
subject 1 were normal. Complex V was not assessed during
these studies. Subsequent blue-native PAGE (BN-PAGE)
with in-gel activity staining showed qualitatively
decreased activity of complex V (Figure S2). For subject 2,
complexes I–IV of the mitochondrial respiratory chain
were all within normal ranges in muscle, as were routine
histology and histochemistry. Pyruvate dehydrogenase ac-
tivity was normal in cultured skin fibroblasts. Subsequent
analysis of the activity of respiratory chain complexes in fi-
broblasts from each affected individual showed a marked
decrease in complex V enzymatic activity (Table 1).
Analysis of mtDNA from blood in both affected
individuals showed no mtDNA rearrangements or point
mutations, and the mtDNA copy number was normal.
Whole-exome sequencing (WES) was performed according
to previously described methodologies and filtering pipe-
lines.10–13 In subject 1, exome sequencing was performed
with VCRome 2.1 in-solution exome probes, as well as
additional probes for over 2,600 Mendelian-disease-related
genes. Library DNA was sequenced on an Illumina HiSeq
for 100 bp paired-end reads. Data analysis was performed
with Mercury 1.0 and was followed by reanalysis using
phenotype- and inheritance-model-based filters with Inge-
nuity Variant Analysis (QIAGEN) and a curated list of mito-
chondrial expressed genes. Variants were confirmed by
Sanger sequencing of DNA samples from the affected sub-
ject and parents. In subject 2, exome sequencing was per-
formed in the family trio with Agilent SureSelectXT All
Exon V5 on a HiSeq 2500 with 100 bp paired-end reads.
Variant calls were generated with an in-house pipeline as
previously described with minor alterations.10 Variant files
were annotated with respect to genes and variant func-
tional consequences with the ANNOVAR tool. Further
annotation included information on variant novelty and
estimated population frequencies from cross-referencing
identified variants with publicly available data and
>1,000 control exomes processed with a Novoalign-based
pipeline.
In both subjects, WES identified biallelic variants in
ATP5F1D (formerly ATP5D [MIM: 603150; GenBank:
NM_001687.4]), which encodes the F1 d subunit of
complex V.14 ATP5F1D is located at 19p13.3 (1,241,750–
1,244,825 [GRCh38.p7]). The predominant transcript
consists of four exons encoding a 146 amino acid mature
protein with a 22 amino acid presequence.14 Research496 The American Journal of Human Genetics 102, 494–504, Marchreanalysis of proband-only clinical WES data from subject
1 identified a homozygous c.245C>T (p.Pro82Leu) variant
in ATP5F1D. Sanger sequencing confirmed bi-parental in-
heritance of the c.245C>T variant (Figure 1A). There was
no detectable abnormality in the abundance or splicing
of the ATP5F1D transcript (Figure S3). In parallel, WES
was undertaken in the family trio of subject 2, revealing
a homozygous c.317T>G (p.Val106Gly) variant in exon
3 of ATP5F1D. Analysis of WES and Sanger confirmation
in the parents demonstrated bi-parental inheritance of
the c.317T>G (p.Val106Gly) variant (Figure 1A). The iden-
tified variants (p.Pro82Leu and p.Val106Gly) affect highly
conserved amino acids (Figure 1B). The c.245C>T variant
has been observed in 1 of 142,292 total alleles (1 of
23,192 alleles of Latino ethnicity) in the gnomAD dataset
and has not been seen in other publicly searchable data-
sets, whereas c.317T>G had not been observed in any
dataset.16 In silico structural modeling indicated that each
amino acid variant induces a change in the predicted pro-
tein structure (Figure 1C).15
Although the two subjects both had features of mito-
chondrial disease and metabolic decompensation, they
differed in that subject 1 presented a few days after birth,
had elevated creatine kinase, and had normal brain MRI.
Subject 2 was not evaluated for mitochondrial phenotypes
until after 4 years of age. Because both had homozygous
missense variants in ATP5F1D and because no disease
annotation for ATP5F1D is known, we undertook addi-
tional studies in subject cells and in Drosophila mela-
nogaster to determine whether these missense changes
were pathogenic.
To investigate the functional effects of the identified
ATP5F1D variants, we performed OXPHOS protein anal-
ysis from cultured skin fibroblasts of each affected individ-
ual. Immunoblotting of protein extracts from subject
fibroblasts showed that steady-state amounts of ATP5F1D
were not affected (Figure 2A). However, other complex
V subunits (ATP5F1A, ATP5F1B, and ATP5PO) were clearly
decreased in abundance (Figure 2A). Double immunofluo-
rescence staining of fibroblasts from subjects 1 and
2 (Figure S4) revealed lower signal of the complex V sub-
unit ATP5F1A than of that in age-matched control cells,
confirming abnormality of complex V. The abundance of
other OXPHOS complex subunits was not decreased,
whereas complex V subunits showed a marked reduction
(Figure 2B). This was confirmed by BN-PAGE analysis,
which showed a loss of complex Vassembly, whereas other
complexes were relatively unaffected (Figure 2C). We
confirmed these findings in skeletal muscle extracts from
subject 2, given that steady-state amounts of CI–CIV sub-
units and complexes were not affected, whereas the
amounts of complex V subunit ATP5F1A (Figure 2D) and
fully assembled complex V (Figure 2E) were markedly
decreased. These data show that cells from the subjects ex-
hibited reduced amounts of complex V. We posit that the
missense changes present in both subjects do not alter
the amount of ATP5F1D but instead lead to an inability1, 2018
Table 1. Genetic, Biochemical, and Clinical Findings in Individuals with Biallelic ATP5F1D Variants
ID Sex
ATP5F1D Variants OXPHOS Activities in Cultured Skin Fibroblasts Clinical Presentation
cDNA (GenBank:
NM_001687.4)
Protein (GenBank:
NP_001687.1)
Respiratory
Chain Complex
Mean Enzyme
Activity (%)
Absolute
Values
Normal Range
of Activities Muscle Biopsy
Age at
Presentation Salient Clinical Features
S1 female c.[245C>T];[245C>T] p.[Pro82Leu];[Pro82Leu] I 83% 24 18–53 normal histology
and respiratory
chain enzymes
2 days hyperammonemia,
cardiomyopathy, lactic
acidosis, rhabdomyolysis
fatigability, short stature
I þ III 267% 310 61–220
II 92% 71 54–124
II þ III 130% 180 79–219
IV 44% 162 270–659
V 5% (YYY) 7 78–287
CS 63% 197 225–459
S2 male c.[317T>G];[317T>G] p.[Val106Gly];[Val106Gly] I 93% 27 18–53 normal histology
and respiratory
chain enzymes
4 years and
10 months
hyperammonemia,
ketoacidosis, delayed speech
I þ III 151% 174 61–220
II 98% 76 54–124
II þ III 139% 193 79–219
IV 142% 519 270–659
V 16% (YY) 23 78–287
CS 101% 314 225–459
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Figure 1. Molecular Genetic Studies of ATP5F1D Variants
(A) Pedigrees and sequencing chromatograms of the two affected
families show segregation of the homozygous ATP5F1D variant
c.245C>T (p.Pro82Leu) in subject 1 and c.317T>G (p.Val106Gly)
in subject 2.
(B) Multiple-sequence alignment confirms evolutionary conserva-
tion of p.Pro82Leu and p.Val106Gly in both human and flies.
(C) SWISS-MODEL-predicted structure of wild-type, p.Pro82Leu,
and p.Val106Gly ATP5F1D.15of ATP5F1D to bind other F1 subunits correctly and thus
result in reduced assembly of complex V.
To assess mitochondrial morphology, we performed
transmission electron microscopy (TEM) on cultured skin
fibroblasts of subject 1 (Figure 3A). The mitochondria in
these fibroblasts were not significantly different in size
from those in control fibroblasts (Figure 3C). However,
they displayed a dramatic decrease in the number of cristae
(Figures 3A and 3D). Induced pluripotent stem cells (iPSCs)
derived from fibroblasts of subject 1 were differentiated
into iPSC-derived cardiomyocytes (Figure S5A). These car-
diomyocytes exhibited both smaller mitochondrial size
and markedly fewer cristae than control cardiomyocytes
(Figures 3B, 3E, and 3F), as well as impaired maximal498 The American Journal of Human Genetics 102, 494–504, Marchrespiration in response to palmitate supplementation
(Figure S5B).
To determine whether the defects seen in complex V in
subject cells were indeed due to the missense variants
found in ATP5F1D, we studied the variants in Drosophila.
ATP synthase d subunit (ATPsynd), the Drosophila homolog
of ATP5F1D, is highly conserved (identity 48%, similarity
65%, DIOPT score 10/12),19 and the affected residues
(Pro82 and Val106) are also conserved (Figure 1B). We
generated transgenic flies harboring a wild-type human
cDNA (UAS-ATP5F1DWT) as well as both variant cDNAs
(UAS-ATP5F1DP82L and UAS-ATP5F1DV106G). The expres-
sion of these cDNAs can be induced by the transcription
factor GAL4.20 To knock down the protein, we ubiqui-
tously expressed a UAS-ATPsynd RNAi by using various
ubiquitous Gal4 drivers, including tub-Gal4, Actin-Gal4,
or da-Gal4.21 All drivers caused lethality (Figure S6C),
consistent with previous observations.22 Pan-neuronal
expression of the ATPsynd RNAi with the elav[C155]-Gal4
driver resulted in lethality early in development
(Figure S6D). This lethality was rescued by expression
of human ATP5F1DWT, but not by expression of
the two human ATP5F1D variants (ATP5F1DP82L
and ATP5F1DV106G) (Figure S6D). These data
indicate that human ATP5F1D is functional in flies and
that the two ATP5F1D variants (ATP5F1DP82L and
ATP5F1DV106G) are not fully functional.
To further examine the effect of these variants in adult
flies, we used the eyeless (ey)-Gal4 driver,23 whose expres-
sion is restricted to the eye, antenna, and part of the
brain. Expression of ATPsynd RNAi in the developing
eye, brain, and antenna with the ey-Gal4 driver caused
pupal lethality and a near-complete loss of the head
(Figures 4A–4C). This lethality and the development of
the eye, antenna, and brain were fully rescued by expres-
sion of human ATP5F1DWT (Figure 4A). Expression of
the two human ATP5F1D variants (ATP5F1DP82L and
ATP5F1DV106G) in flies in which the endogenous
ATPsynd had been knocked down by the eyGal4 driver
rescued lethality (Figure 4A). However, the animals
rescued by the eyGal4 driver retained abnormal eye and
antennal phenotypes (Figures 4D–4K). Interestingly,
rescue with the ATP5F1DV106G allele corresponding to
subject 2 showed more severe phenotypes than rescue
with ATP5F1DP82L—the ATP5F1DV106G allele only
partially rescued lethality, elicited a glossy-eye phenotype
less frequently than ATP5F1DP82 expression, and caused
more severe defects in electroretinogram recordings
than did the ATP5F1DP82 allele (Figure S7). Hence, the
mutant ATP5F1D proteins are not fully functional
when tested in flies, and the function of ATP5F1DV106G
is more severely affected than ATP5F1DP82L in this
system.
To evaluate the metabolic effects of these mitochondrial
defects, we performed exploratory analyses of untargeted
plasma metabolite and lipid profiles in samples from
subject 1 and in transgenic flies. Plasma metabolomic1, 2018
Figure 2. Biallelic Variants in ATP5F1D
Impair the Steady-State Amounts of the
F1FO ATP Synthase Complex and Subunits
Immunoblot and BN-PAGE analysis were
carried out on subject cultured skin fibro-
blasts and skeletal muscle samples
as previously described.11,17,18 SDS-PAGE
and immunoblot analysis of whole-cell ly-
sates (40 mg) isolated from cultured skin fi-
broblasts of affected subjects 1 (S1) and 2
(S2) and age-matched control individuals
show (A) the steady-state amounts of
complex V subunits (ATP5F1A, ATP5F1B,
ATP5F1D, and ATP5PO) and (B) the
amounts of individual OXPHOS complex
subunits. One-dimensional BN-PAGE anal-
ysis was performed for assembled OXPHOS
complexes in n-dodecyl-b-D-maltoside
(DDM; 850520P, Sigma)-solubilized mito-
chondrial extracts isolated from control,
S1, and S2 fibroblasts (C). Steady-state
amounts (D) and assembly (E) of OXPHOS
complexes and subunits in DDM-solubi-
lized mitochondrial extracts from control
and subject 2 skeletal muscle demonstrate
a decrease in complex V. In (C) and (E),
mitochondrial lysates (100 mg) were loaded
on a 4%–16% native gel (Life Technolo-
gies), and then protein complexes were
immobilized onto polyvinylidene difluor-
ide membranes and subjected to immuno-
blotting with the indicated OXPHOS-sub-
unit-specific antibodies. In (A)–(E),
nuclear-encoded SDHA (ab14715, Abcam)
or porin (VDAC1, ab14734, Abcam) was
used as a loading control. Abbreviations
are as follows: BN, blue native; CI, complex
I; CII, complex II; CIII, complex III; CIV,
complex IV; and CV, complex V.profiling24,25 revealed accumulation of the TCA cycle
intermediates malic acid and citric acid, as well as
compensatory changes in branched-chain amino acid
metabolism (Figure S8 and Table S1). Plasma lipidomic
analysis comparing subject 1 samples with those of
136 unrelated control samples revealed increases in long-
chain acylcarnitines (C12:1, C14:1, and C16), decreases
in dihydroceramides and ceramides, and elevated
sphingomyelin, lactosylceramide, and ganglioside (GM3)
lipids26–29 (Figure S9A and Table S2). Similar changes in
long-chain acylcarnitines were seen in flies with mildly
reduced ATPsynd expression driven by attenuated expres-
sion of ATPsynd RNAi (C12 and C14:1), wheras alterations
in cardiolipin (CL) profile lipids, highly enriched in mito-
chondrial inner membranes,30 (Figure S9B and Table S3)
were uniquely observed in fly homogenates. Together,
these data suggest that an impairment in mitochondrial
fatty acid oxidation might contribute to the hypoglycemia
observed in the two subjects.
In summary, we present compelling data that biallelic
missense variants inATP5F1D result in amitochondrial dis-The Ameriorder that manifests in childhoodwith episodic decompen-
sation featuring lactic acidosis and hyperammonemia
accompanied by ketoacidosis or hypoglycemia. Chronic
manifestations include developmental delay, easy fatigu-
ability, and 3-methylglutaconic aciduria. Interestingly, the
two subjects exhibited different ages of onset and differed
with respect to the presence of elevated creatine kinase
and encephalopathy. Initial clinical studies in both subjects
showed normal respiratory chain enzyme profiles
(measuring complexes I–IV), and WES was undertaken on
account of a clear mitochondrial and/or metabolic pheno-
type. The pathogenicity of ATP5F1D variants (c.245C>T
[p.Pro82Leu] and c.317T>G [p.Val106Gly]) identified in
these two subjects was confirmed by the segregation of var-
iants with disease in each family (Figure 1), demonstration
of severe reduction of complex Vactivity in subject cultured
skin fibroblasts (Figure 2), documentation of fewer mito-
chondrial cristae in subject cells (Figure 3), and demonstra-
tion of incomplete phenotypic rescue by subject ATP5F1D
variants in Drosophila lacking ATPsynd but complete rescue
with normal human ATP5F1D (Figure 4).can Journal of Human Genetics 102, 494–504, March 1, 2018 499
Figure 3. Subject-Derived Cells Carrying
a c.245C>T (p.Pro82Leu) ATP5F1D Variant
Exhibit a Decreased Number of Cristae
(A) TEM of cultured skin fibroblasts from
an unaffected control individual and sub-
ject 1 (S1) (p.Pro82Leu).
(B) TEM of iPSC-derived cardiomyocytes.
Red arrows show mitochondria devoid
of cristae in cells from affected individual
S1 (p.Pro82Leu). Black arrows indicate
nascent sarcomeres. Scale bar: 500 nm.
(C) Quantification of mitochondrial size in
control and subject 1 (p.Pro82Leu) fibro-
blasts. Error bars indicate SEM, and p values
were calculated by Student’s t test. N.S. in-
dicates not statistically significant.
(D) Quantification of the number of cristae
per mitochondrion in control and subject
1 (p.Pro82Leu) fibroblasts. Error bars indi-
cate SEM, and p values were calculated by
Student’s t test (***p < 0.001).
(E) Quantification of the mitochondrial
area in control and subject 1 (p.Pro82Leu)
iPSC-derived cardiomyocytes. Quartiles
and minimum and maximum values are
shown, and p values were calculated by
an unpaired two-tailed t test (p ¼ 0.03).
(F) Quantification of the number of cristae
per mitochondrion in control and subject
1 (p.Pro82Leu) iPSC-derived cardiomyo-
cytes. Quartiles and minimum and
maximum values are shown, and p
values were calculated by an unpaired t
test (p < 0.001).Loss of cristae in mitochondria is consistent with phe-
notypes associated with other complex V mitochondrial
mutants. Indeed, ATP synthase forms dimers and oligo-
mers within the mitochondrial inner membrane, and
these oligomers have been shown to be important for
cristae formation.31,32 Furthermore, individuals with mu-
tations in MT-ATP6 (MIM: 516060) have disrupted
cristae,33 and loss of ATPsynε (the homolog of human
ATP5F1E) or ATPsyng (the homolog of human ATP5F1C)
in flies causes a decreased number of cristae.22,34 The
glossy-eye phenotype provides an additional link between
our observation and OXPHOS genes. Indeed, loss of the
NADH dehydrogenase (ubiquinone) PDSW subunit
(Pdsw) and cytochrome c oxidase subunit of Va (CoVa)
in the fly eye causes glossy eyes.35 These glossy eyes can
be considered a ‘‘phenolog’’ or a non-obvious phenotypic
link to mitochondrial disease in humans.36500 The American Journal of Human Genetics 102, 494–504, March 1, 2018Complex V deficiencies have been
reported to be due to mutations in
the mtDNA-encoded MT-ATP633,37
and MT-ATP8 (MIM: 516070),38–40
as well as the nuclear-encoded
ATPAF2 (ATP12 [MIM: 608918])41,42
and the F1 subunits ATP5F1E
(ATP5E [MIM: 606153])43 and
ATP5F1A (ATP5A1 [MIM:
164360]).44,45 The most commonnuclear genetic cause of complex V deficiency, however,
is associated with TMEM70 (MIM: 612418),46 which en-
codes a protein required for the biogenesis and stability
of complex V.47 The presentation of disorders of complex
V has often been described as an early-onset encephalo-
cardiomyopathy that is typically observed in individuals
with TMEM70 mutations.46,48,49 However, there can
be significant clinical heterogeneity associated with
different variants in the same gene: for example, muta-
tions in MT-ATP6 lead to a variety of clinical syndromes,
including neurogenic muscle weakness, ataxia, and
retinitis pigmentosa (MIM: 551500), Leigh syndrome
(MIM: 256000), mitochondrial infantile bilateral striatal
necrosis (MIM: 500003), and Charcot-Marie-Tooth hered-
itary neuropathy.50,51 The findings of hyperammonemia
and increased 3-methylglutaconic aciduria in both sub-
jects during acute episodes of metabolic decompensation
Figure 4. ATP5F1D p.Pro82Leu and
p.Val106Gly Are Partial Loss-of-Function
Variants
(A) The observed/expected ratio of flies
shows the rescue of lethality by the human
genes including both variants in the
Drosophila null background.
(B and C) Expression of ATPsynd RNAi by
ey-Gal4 caused pupal lethality and an
extremely reduced head size (ey-Gal4/UAS-
ATPsynd RNAi; UAS-LacZ/þ) (C), whereas
control animals without the ey-Gal4 driver
(UAS-ATPsynd RNAi/þ; UAS-LacZ) showed
normal head development (B).
(D–F) Light micrographs of fly eyes ex-
pressing ey-Gal4 and ATPsynd RNAi
together with UAS-ATP5F1DWT (D), UAS-
ATP5F1DP82L (E), or UAS-ATP5F1DV106G
(F). We found that expression of
ATP5F1DWT rescued the tiny-head pheno-
type caused by knockdown of ATPsynd
(D). However, a portion of adult flies
expressing ATPsynd RNAi together with
ATP5F1DP82L or ATP5F1DV106G exhibited
abnormal eye morphology, including
glassy eyes, small eyes, and bar eyes
(E and F). Quantification of the pheno-
types shows that expression of
ATP5F1DV106G causes more severe defects
than ATP5F1DP82L (J).
(G–I) Light micrographs of fly antenna
expressing ey-Gal4 and ATPsynd RNAi
together with UAS-ATP5F1DWT (G), UAS-
ATP5F1DP82L (H), orUAS-ATP5F1DV106G (I).
(K) Quantification of the antenna
morphology phenotypes described in
(G)–(I).provides an important phenotypic link to complex V de-
ficiencies because these are also prominent in individuals
with TMEM70,46,52 ATP5F1E,43 and ATPAF241,42 muta-
tions. Proper management of hyperammonemic meta-
bolic crises early in life appears to be vital for improving
the prognosis of individuals with TMEM70 muta-
tions.46,52 Persistent 3-methylglutaconic aciduria is also
observed in other complex V deficiency syndromes but
is additionally seen in a broader range of metabolic disor-
ders.53 In summary, the shared and divergent pheno-
types observed in our two subjects and the observation
that the two variants are both deleterious but to different
degrees when tested in Drosophila argue for these biallelic
mutations in ATP5F1D as pathogenic for disease in both
subjects.The American Journal of Human GWe anticipate that additional
cases of the ATP5F1D-related mito-
chondrial disorder will be identified,
providing us with the opportunity
to better define the clinical spectrum
of the condition. Given the dramatic
phenotype associated with the severe
loss of ATP5F1D function in a model
organism (Figure 4),22 it is possiblethat other variants associated with varying phenotypes
will also be discovered. At present, the defining features
appear to be mild developmental disability, easy fatiga-
bility, and episodic biochemical decompensation
with acute illness, which can be profound at initial
presentation.
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